Literature DB >> 29024785

Slow Intrathecal Injection of rAAVrh10 Enhances its Transduction of Spinal Cord and Therapeutic Efficacy in a Mutant SOD1 Model of ALS.

Dongxiao Li1, Chong Liu1, Chunxing Yang2, Dan Wang3, Dongxia Wu1, Yinkuang Qi1, Qin Su3, Guangping Gao4, Zuoshang Xu5, Yansu Guo6.   

Abstract

Mutant SOD1 causes amyotrophic lateral sclerosis (ALS) by a dominant gain of toxicity. Previous studies have demonstrated therapeutic potential of mutant SOD1-RNAi delivered by intrathecal (IT) injection of recombinant adeno-associated virus (rAAV). However, optimization of delivery is needed to overcome the high degree of variation in the transduction efficiency and therapeutic efficacy. Here, on the basis of our previously defined, efficient IT injection method, we investigated the influence of injection speed on transduction efficiency in the central nervous system (CNS). We demonstrate that slow IT injection results in higher transduction of spinal cord and dorsal root ganglia (DRG) while fast IT injection leads to higher transduction of brain and peripheral organs. To test how these effects influence the outcome of RNAi therapy, we used slow and fast IT injection to deliver rAAVrh10-GFP-amiR-SOD1, a rAAV vector that expresses GFP and an artificial miRNA targeting SOD1, in SOD1-G93A mice. Both slow and fast IT injection produced therapeutic efficacy but the slow injection trended slightly toward a better outcome than the fast injection. These results demonstrate that IT injection speed influences the predominance of gene delivery at different CNS sites and should be taken into consideration in future therapeutic trials involving IT injection.
Copyright © 2017 IBRO. All rights reserved.

Entities:  

Keywords:  AAV; SOD1-G93A; amyotrophic lateral sclerosis; gene therapy; intrathecal

Mesh:

Substances:

Year:  2017        PMID: 29024785      PMCID: PMC5757625          DOI: 10.1016/j.neuroscience.2017.10.001

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.708


  22 in total

1.  Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats.

Authors:  J Hordeaux; L Dubreil; J Deniaud; F Iacobelli; S Moreau; M Ledevin; C Le Guiner; V Blouin; J Le Duff; A Mendes-Madeira; F Rolling; Y Cherel; P Moullier; M-A Colle
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

Review 2.  Developments in treatments for amyotrophic lateral sclerosis via intracerebroventricular or intrathecal delivery.

Authors:  Philip Van Damme; Wim Robberecht
Journal:  Expert Opin Investig Drugs       Date:  2014-05-09       Impact factor: 6.206

3.  Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.

Authors:  Gretchen M Thomsen; Genevieve Gowing; Jessica Latter; Maximus Chen; Jean-Philippe Vit; Kevin Staggenborg; Pablo Avalos; Mor Alkaslasi; Laura Ferraiuolo; Shibi Likhite; Brian K Kaspar; Clive N Svendsen
Journal:  J Neurosci       Date:  2014-11-19       Impact factor: 6.167

4.  A Single Injection of Recombinant Adeno-Associated Virus into the Lumbar Cistern Delivers Transgene Expression Throughout the Whole Spinal Cord.

Authors:  Yansu Guo; Dan Wang; Tao Qiao; Chunxing Yang; Qin Su; Guangping Gao; Zuoshang Xu
Journal:  Mol Neurobiol       Date:  2015-06-07       Impact factor: 5.590

5.  Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.

Authors:  Hongyan Wang; Bin Yang; Linghua Qiu; Chunxing Yang; Joshua Kramer; Qin Su; Yansu Guo; Robert H Brown; Guangping Gao; Zuoshang Xu
Journal:  Hum Mol Genet       Date:  2013-09-18       Impact factor: 6.150

6.  Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders.

Authors:  Adam K Bevan; Sandra Duque; Kevin D Foust; Pablo R Morales; Lyndsey Braun; Leah Schmelzer; Curtis M Chan; Mary McCrate; Louis G Chicoine; Brian D Coley; Paul N Porensky; Stephen J Kolb; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

7.  Integration of the subarachnoid space and lymphatics: is it time to embrace a new concept of cerebrospinal fluid absorption?

Authors:  Lena Koh; Andrei Zakharov; Miles Johnston
Journal:  Cerebrospinal Fluid Res       Date:  2005-09-20

8.  Structural and functional features of central nervous system lymphatic vessels.

Authors:  Antoine Louveau; Igor Smirnov; Timothy J Keyes; Jacob D Eccles; Sherin J Rouhani; J David Peske; Noel C Derecki; David Castle; James W Mandell; Kevin S Lee; Tajie H Harris; Jonathan Kipnis
Journal:  Nature       Date:  2015-06-01       Impact factor: 49.962

9.  Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.

Authors:  S J Gray; S Nagabhushan Kalburgi; T J McCown; R Jude Samulski
Journal:  Gene Ther       Date:  2013-01-10       Impact factor: 5.250

10.  SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice.

Authors:  Elisabeth Dirren; Julianne Aebischer; Cylia Rochat; Christopher Towne; Bernard L Schneider; Patrick Aebischer
Journal:  Ann Clin Transl Neurol       Date:  2015-01-15       Impact factor: 4.511

View more
  7 in total

1.  Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space.

Authors:  Dan Wang; Jia Li; Karen Tran; Daniel R Burt; Li Zhong; Guangping Gao
Journal:  Hum Gene Ther Methods       Date:  2018-03-29       Impact factor: 2.396

2.  Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy.

Authors:  Yi Gong; Anna Berenson; Fiza Laheji; Guangping Gao; Dan Wang; Carrie Ng; Adrienn Volak; Rene Kok; Vasileios Kreouzis; Inge M Dijkstra; Stephan Kemp; Casey A Maguire; Florian Eichler
Journal:  Hum Gene Ther       Date:  2018-12-18       Impact factor: 5.695

Review 3.  Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.

Authors:  Andrew P Tosolini; James N Sleigh
Journal:  Front Mol Neurosci       Date:  2017-12-07       Impact factor: 5.639

Review 4.  Optimization of AAV vectors to target persistent viral reservoirs.

Authors:  Rossana Colón-Thillet; Keith R Jerome; Daniel Stone
Journal:  Virol J       Date:  2021-04-23       Impact factor: 5.913

Review 5.  The Biogenesis of miRNAs and Their Role in the Development of Amyotrophic Lateral Sclerosis.

Authors:  Jinmeng Liu; Fenghua Zhou; Yingjun Guan; Fandi Meng; Zhenhan Zhao; Qi Su; Weiwei Bao; Xuemei Wang; Jiantao Zhao; Zijun Huo; Lingyun Zhang; Shuanhu Zhou; Yanchun Chen; Xin Wang
Journal:  Cells       Date:  2022-02-07       Impact factor: 6.600

Review 6.  Overcoming delivery barriers in immunotherapy for glioblastoma.

Authors:  Yuan Rui; Jordan J Green
Journal:  Drug Deliv Transl Res       Date:  2021-05-30       Impact factor: 4.617

Review 7.  Current Status of microRNA-Based Therapeutic Approaches in Neurodegenerative Disorders.

Authors:  Sujay Paul; Luis Alberto Bravo Vázquez; Samantha Pérez Uribe; Paula Roxana Reyes-Pérez; Ashutosh Sharma
Journal:  Cells       Date:  2020-07-15       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.